全文获取类型
收费全文 | 12323篇 |
免费 | 653篇 |
国内免费 | 819篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 254篇 |
妇产科学 | 185篇 |
基础医学 | 843篇 |
口腔科学 | 33篇 |
临床医学 | 1240篇 |
内科学 | 3307篇 |
皮肤病学 | 35篇 |
神经病学 | 927篇 |
特种医学 | 515篇 |
外国民族医学 | 1篇 |
外科学 | 2161篇 |
综合类 | 1391篇 |
预防医学 | 530篇 |
眼科学 | 57篇 |
药学 | 982篇 |
7篇 | |
中国医学 | 518篇 |
肿瘤学 | 787篇 |
出版年
2023年 | 225篇 |
2022年 | 356篇 |
2021年 | 507篇 |
2020年 | 473篇 |
2019年 | 275篇 |
2018年 | 292篇 |
2017年 | 317篇 |
2016年 | 363篇 |
2015年 | 379篇 |
2014年 | 860篇 |
2013年 | 910篇 |
2012年 | 734篇 |
2011年 | 826篇 |
2010年 | 707篇 |
2009年 | 592篇 |
2008年 | 691篇 |
2007年 | 672篇 |
2006年 | 577篇 |
2005年 | 458篇 |
2004年 | 359篇 |
2003年 | 321篇 |
2002年 | 259篇 |
2001年 | 306篇 |
2000年 | 234篇 |
1999年 | 183篇 |
1998年 | 165篇 |
1997年 | 135篇 |
1996年 | 156篇 |
1995年 | 166篇 |
1994年 | 135篇 |
1993年 | 115篇 |
1992年 | 132篇 |
1991年 | 98篇 |
1990年 | 113篇 |
1989年 | 108篇 |
1988年 | 84篇 |
1987年 | 59篇 |
1986年 | 58篇 |
1985年 | 62篇 |
1984年 | 44篇 |
1983年 | 34篇 |
1982年 | 52篇 |
1981年 | 39篇 |
1980年 | 38篇 |
1979年 | 27篇 |
1978年 | 30篇 |
1977年 | 25篇 |
1976年 | 14篇 |
1974年 | 7篇 |
1973年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Association of Multimodal Pain Control with Patient-Reported Outcomes in Children Undergoing Surgery
《Journal of pediatric surgery》2023,58(6):1206-1212
IntroductionOur aim was to describe practices in multimodal pain management at US children's hospitals and evaluate the association between non-opioid pain management strategies and pediatric patient-reported outcomes (PROs).MethodsData were collected as part of the 18-hospital ENhanced Recovery In CHildren Undergoing Surgery (ENRICH-US) clinical trial. Non-opioid pain management strategies included use of preoperative and postoperative non-opioid analgesics, regional anesthetic blocks, and a biobehavioral intervention. PROs included perioperative nervousness, pain-related functional disability, health-related quality of life (HRQoL). Associations were analyzed using multinomial logistic regression models.ResultsAmong 186 patients, 62 (33%) received preoperative analgesics, 186 (100%) postoperative analgesics, 81 (44%) regional anesthetic block, and 135 (73%) used a biobehavioral intervention. Patients were less likely to report worsened as compared to stable nervousness following regional anesthetic block (relative risk ratio [RRR]:0.31, 95% confidence interval [CI]:0.11–0.85), use of a biobehavioral technique (RRR:0.26, 95% CI:0.10–0.70), and both in combination (RRR:0.08, 95% CI:0.02–0.34). There were no associations of non-opioid pain control modalities with pain-related functional disability or HRQoL.ConclusionUse of postoperative non-opioid analgesics have been largely adopted, while preoperative non-opioid analgesics and regional anesthetic blocks are used less frequently. Regional anesthetic blocks and biobehavioral interventions may mitigate postoperative nervousness in children.Level of evidenceIII. 相似文献
2.
Yi-Nan Ding Ming Xue Qiu-Sha Tang Li-Jun Wang Hui-Yan Ding Han Li Cheng-Cheng Gao Wei-Ping Yu 《World journal of gastroenterology : WJG》2022,28(37):5403-5419
Gastrointestinal cancer (GIC) is the most common cancer with a poor prognosis. Currently, surgery is the main treatment for GIC. However, the high rate of postoperative recurrence leads to a low five-year survival rate. In recent years, immunotherapy has received much attention. As the only immunotherapy drugs approved by the Food and Drug Administration (FDA), immune checkpoint blockade (ICB) drugs have great potential in cancer therapy. Nevertheless, the efficacy of ICB treatment is greatly limited by the low immunogenicity and immunosuppressive microenvironment of GIC. Therefore, the targets of immunotherapy have expanded from ICB to increasing tumor immunogenicity, increasing the recruitment and maturation of immune cells and reducing the proportion of inhibitory immune cells, such as M2-like macrophages, regulatory T cells and myeloid-derived suppressor cells. Moreover, with the development of nanotechnology, a variety of nanoparticles have been approved by the FDA for clinical therapy, so novel nanodrug delivery systems have become a research focus for anticancer therapy. In this review, we summarize recent advances in the appli cation of immunotherapy-based nanoparticles in GICs, such as gastric cancer, hepatocellular carcinoma, colorectal cancer and pancreatic cancer, and described the existing challenges and future trends. 相似文献
3.
《Journal of infection and chemotherapy》2022,28(4):548-553
IntroductionCOVID-19 patients have been reported to have digestive symptoms with poor outcome. Ivermectin, an antiparasitic drug, has been used in COVID-19 patients. The objective of this study was to evaluate whether ivermectin has effects on gastrointestinal complications and ventilator-free days in ventilated patients with COVID-19.MethodsCOVID-19 patients who were mechanically ventilated in the ICU were included in this study. The ventilated patients who received ivermectin within 3 days after admission were assigned to the Ivermectin group, and the others were assigned to the Control group. Patients in the Ivermectin group received ivermectin 200 μg/kg via nasal tube. The incidence of gastrointestinal complications and ventilator-free days within 4 weeks from admission were evaluated as clinical outcomes using a propensity score with the inverse probability weighting method.ResultsWe included 88 patients in this study, of whom 39 patients were classified into the Ivermectin group, and 49 patients were classified into the Control group. The hazard ratio for gastrointestinal complications in the Ivermectin group as compared with the Control group was 0.221 (95% confidence interval [CI], 0.057 to 0.855; p = 0.029) in a Cox proportional-hazard regression model. The odds ratio for ventilator-free days as compared with the Control group was 1.920 (95% CI, 1.076 to 3.425; p = 0.027) in a proportional odds logistic regression model.ConclusionsIvermectin improved gastrointestinal complications and the number of ventilator-free days in severe COVID-19 patients undergoing mechanical ventilation. Prevention of gastrointestinal symptoms by SARS-Cov-2 might be associated with COVID-19 outcome. 相似文献
4.
目的 探讨生长抑素对急腹症患儿术后胃肠功能及应激水平的影响。 方法 选取2019年8月至2021年6月徐州市儿童医院收治的行手术治疗的102例急腹症患儿为研究对象。将患儿随机分为观察组和对照组,每组各51例。对照组患儿术后给予止血、抗感染等常规治疗,观察组在常规治疗的基础上加用生长抑素。术前、术后第1天及术后第5天采集两组患儿外周血,比较两组患儿血清血管内皮素-1(endothelin-1,ET-1)、促肾上腺皮质激素(adrenocorticotropic hormone,ACTH)、皮质醇(cortisol,Cor)及胃泌素、胃动素水平,以及两组患儿术后恢复情况及并发症发生率。 结果 术前两组患儿血清ET-1、ACTH、Cor、胃动素及胃泌素水平差异无统计学意义(P >0.05)。术后第1天、第5天,观察组患儿血清ET-1、ACTH、Cor水平均显著低于对照组(P <0.05);术后第5天,观察组患儿胃动素与胃泌素水平均高于对照组(P <0.05)。术后观察组患儿首次肛门排气时间、肠鸣音恢复时间、首次排便时间、住院时间均较对照组缩短(P <0.05)。观察组并发症发生率(6%)显著低于对照组(24%,P <0.05)。 结论 生长抑素可显著降低急腹症患儿术后应激反应,改善胃肠功能,降低并发症发生率,有益于疾病预后。 相似文献
5.
6.
7.
8.
9.
10.